Associated Papers
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis.
Salani F et al.
Esmo Open, 2025
Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
Terashima Y et al.
Cancer Science, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Advances in the diagnosis and treatment of MET-variant digestive tract tumors.
Zhang C et al.
World Journal of Gastrointestinal Oncology, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
The genomic landscape of lung cancer in never-smokers from the Women's Health Initiative.
Moorthi S et al.
Jci Insight, 2024
Integrative Analysis of Germline Rare Variants in Clear and Non-clear Cell Renal Cell Carcinoma.
Han SH et al.
European Urology Open Science, 2024
Detection of MET gene somatic mutations in hepatocellular carcinoma of Egyptian patients using next-generation sequencing.
Ahmed E et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, 2023
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
Yao Y et al.
Respiratory Research, 2023
Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma.
Han S et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
An In silico Approach towards Finding the Cancer-Causing Mutations in Human MET Gene.
Laskar FS et al.
International Journal of Genomics, 2023
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies.
Rivas S et al.
International Journal of Molecular Sciences, 2022
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Sebai M et al.
Human Mutation, 2022
Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase.
Yao HP et al.
Therapeutic Advances in Medical Oncology, 2021
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Yang J et al.
Frontiers in Oncology, 2021
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R et al.
Nature Reviews. Clinical Oncology, 2020
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.
Schoenfeld AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice.
Singh AP et al.
Cancers, 2020
Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L et al.
Plos Genetics, 2018
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Cortot AB et al.
Journal of the National Cancer Institute, 2017
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Hughes PE et al.
Molecular Cancer Therapeutics, 2016
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2013
The role of the c-Met pathway in lung cancer and the potential for targeted therapy.
Sattler M et al.
Therapeutic Advances in Medical Oncology, 2011
Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL et al.
Biochemistry, 2009
Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008